-
1 Comment
HANDOK Inc is currently in a long term downtrend where the price is trading 6.7% below its 200 day moving average.
From a valuation standpoint, the stock is 90.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.8.
HANDOK Inc's total revenue rose by 2.3% to $132B since the same quarter in the previous year.
Its net income has dropped by 26.7% to $12B since the same quarter in the previous year.
Finally, its free cash flow grew by 41.6% to $5B since the same quarter in the previous year.
Based on the above factors, HANDOK Inc gets an overall score of 3/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| ISIN | KR7002390003 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | None |
|---|---|
| Market Cap | 154B |
| Target Price | 50000 |
| Dividend Yield | 1.7% |
| Beta | 0.44 |
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002390.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
